Q-Line Biotech FY26 net profit rises to ₹56.95 crore
Q-Line Biotech reported a net profit of ₹56.95 crore for FY26, up from ₹47.40 crore in FY25, driven by a 9% rise in revenue to ₹341.16 crore and improved margins. The company's Board approved the audited financial results on June 17, 2026, with an unmodified opinion from the statutory auditor.
*this image is generated using AI for illustrative purposes only.
Q-Line Biotech reported a net profit of ₹56.95 crore for the financial year ended March 31, 2026 (FY26), an increase from ₹47.40 crore in the previous year, driven by higher sales of manufactured products and improved operational efficiencies. Revenue from operations rose 9% to ₹341.16 crore from ₹313.07 crore in FY25. The Board of Directors approved the audited standalone and consolidated financial results for the year ended March 31, 2026, at a meeting held on June 17, 2026.
Financial Performance
The company's profitability improved as the gross margin expanded to 60.8% in FY26 from 53.3% in FY25. EBITDA for the year stood at ₹98.10 crore, compared to ₹70.60 crore in the prior year, with the EBITDA margin improving to 28.7%. Profit after tax for the year was ₹56.95 crore, up from ₹47.40 crore in FY25. The statutory auditor, R K Jagetiya & Co, issued an unmodified opinion on the financial results.
| Financial Metric (₹ Crores) | FY26 | FY25 |
|---|---|---|
| Revenue from Operations | 341.16 | 313.07 |
| EBITDA | 98.10 | 70.60 |
| Profit After Tax | 56.95 | 47.40 |
| Gross Margin | 60.8% | 53.3% |
| EBITDA Margin | 28.7% | 22.5% |
Operational Highlights
Reagents remained the primary growth driver, with sales of manufactured products increasing significantly during the year. The company commissioned its fourth manufacturing facility in Lucknow, expanding its production capacity. The installation base of the Selectra Pro M fully automated biochemistry analyzer crossed 1,550 instruments, supporting recurring reagent consumption. The company continues to prepare its financial statements under Indian GAAP, exempt from Ind AS due to its listing on the SME Exchange.
Future Outlook
Looking ahead to FY27, Q-Line Biotech targets revenue growth of approximately 30% to 35% while maintaining a focus on profitability and capital efficiency. Management expects the EBITDA margin to remain slightly better than FY26 levels, supported by the increased utilization of new manufacturing facilities and a higher mix of manufactured reagent sales.
What specific strategies will Q-Line Biotech employ to achieve the aggressive 30-35% revenue growth target in FY27?
How will the commissioning of the fourth facility in Lucknow impact production capacity and cost structures in the coming year?
What is the expected timeline for the new manufacturing facility to reach full operational capacity?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
